Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.

Shapiro GI, Kristeleit RS, Burris HA, LoRusso P, Patel MR, Drew Y, Giordano H, Maloney L, Watkins S, Goble S, Jaw-Tsai S, Xiao JJ.

Clin Pharmacol Drug Dev. 2019 Jan;8(1):107-118. doi: 10.1002/cpdd.575. Epub 2018 May 25.

2.

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.

Wilson RH, Evans TJ, Middleton MR, Molife LR, Spicer J, Dieras V, Roxburgh P, Giordano H, Jaw-Tsai S, Goble S, Plummer R.

Br J Cancer. 2017 Mar 28;116(7):884-892. doi: 10.1038/bjc.2017.36. Epub 2017 Feb 21.

3.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR.

N Engl J Med. 2015 Apr 30;372(18):1700-9. doi: 10.1056/NEJMoa1413654.

5.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, van Kalken D, Chaturvedi P, Niu D, Nacht M, Petter RC, Westlin W, Lin K, Jaw-Tsai S, Raponi M, Van Dyke T, Etter J, Weaver Z, Pao W, Singh J, Simmons AD, Harding TC, Allen A.

Cancer Discov. 2013 Dec;3(12):1404-15. doi: 10.1158/2159-8290.CD-13-0314. Epub 2013 Sep 24.

6.

In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models.

Pulido-Rios MT, McNamara A, Obedencio GP, Ji Y, Jaw-Tsai S, Martin WJ, Hegde SS.

J Pharmacol Exp Ther. 2013 Aug;346(2):241-50. doi: 10.1124/jpet.113.203554. Epub 2013 May 17.

PMID:
23685545
7.

A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.

Van Orden LJ, Van Dyke PM, Saito DR, Church TJ, Chang R, Smith JA, Martin WJ, Jaw-Tsai S, Stangeland EL.

Bioorg Med Chem Lett. 2013 Mar 1;23(5):1456-61. doi: 10.1016/j.bmcl.2012.12.061. Epub 2012 Dec 22.

PMID:
23347683
8.

AZD-3043: a novel, metabolically labile sedative-hypnotic agent with rapid and predictable emergence from hypnosis.

Egan TD, Obara S, Jenkins TE, Jaw-Tsai SS, Amagasu S, Cook DR, Steffensen SC, Beattie DT.

Anesthesiology. 2012 Jun;116(6):1267-77. doi: 10.1097/ALN.0b013e31825685a6.

9.

An interspecies extrapolation of the pharmacokinetics of telavancin, a rapidly bactericidal, concentration-dependent antibiotic.

Shaw JP, Jaw-Tsai S.

Xenobiotica. 2011 Jan;41(1):82-9. doi: 10.3109/00498254.2010.525261. Epub 2010 Oct 15.

PMID:
20946087
10.

Pharmacological analysis of the interaction of antimuscarinic drugs at M(2) and M(3) muscarinic receptors in vivo using the pithed rat assay.

Armstrong SR, Briones S, Horger B, Richardson CL, Jaw-Tsai S, Hegde SS.

Naunyn Schmiedebergs Arch Pharmacol. 2008 Jan;376(5):341-9. Epub 2007 Dec 7.

PMID:
18064438
12.

Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.

Steece-Collier K, Chambers LK, Jaw-Tsai SS, Menniti FS, Greenamyre JT.

Exp Neurol. 2000 May;163(1):239-43.

PMID:
10785463
13.

CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents.

Menniti FS, Pagnozzi MJ, Butler P, Chenard BL, Jaw-Tsai SS, Frost White W.

Neuropharmacology. 2000 Apr 27;39(7):1147-55.

PMID:
10760358

Supplemental Content

Loading ...
Support Center